NEXT-GENERATION NK CELL-BASED IMMUNOTHERAPIES FOR HARD-TO-TREAT CANCERS
Associate Professor Fernando S. F. Guimaraes, PhD, GAICD
Group Leader, Translational Innate Immunotherapy
Frazer Institute, Faculty of Medicine,
The University of Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | February 2025
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
A/Prof Guimaraes completed his PhD at the Institut Pasteur and pursued postdoctoral research at QIMR Berghofer and WEHI before joining UQ in 2019. His pioneering work has significantly advanced understanding of immune evasion mechanisms in cancer, leading to potential breakthroughs in NK cell therapies. His research integrates systems biology, experimental oncology, and bioinformatics to design novel, targeted treatments resistant to tumour-induced immunosuppression. His contributions have earned him numerous awards, including the QLD Tall Poppy, UQ Frazer Institute Rising Star, Translational Research Institute – Connecting with the Clinic Awards.
He has published extensively in top-tier journals, secured and led major research funding (NHMRC, MRFF, US DoD) focused on NK cell therapies. A/Prof Guimaraes also plays a key role in mentoring early-career researchers, serving as the Chair of the Research Committee at Cure Cancer Australia and leading multiple international collaborations.
Source: supplied
https://orcid.org/0000-0002-2037-8946
-
Infections and other lung diseases using models of human lung tissue grown from stem cells
Dr Rhiannon Werder is a Team Leader at Murdoch Children’s Research Institute leading a multidisciplinary team, combining expertise in stem cell biology and immunology, to develop new therapies for lung diseases. Her research centres around induced pluripotent stem cells to investigate respiratory diseases, spanning acute respiratory infections to chronic lung diseases. Using stem cells, Dr Werder’s team creates models of human lung tissue. With these models, Dr Werder is investigating how human-specific pathogens infect different regions of the lung, the ensuing immune responses, and how the lung repairs itself after infections, especially in people with preexisting lung diseases.
-
Muscle Cell Communication and Repair
Dr. William Roman is a Group Leader at the Australian Regenerative Medicine Institute (ARMI) at Monash University. He obtained his PhD from Paris Descartes University and Freie University of Berlin, focusing on nuclear positioning during skeletal muscle development. Dr. Roman’s research journey has taken him across the globe, including postdoctoral work in Barcelona, tissue engineering in Lisbon, and a brief stint at Stanford University.
At ARMI, Dr. Roman leads innovative research on intercellular communication within muscle organs. His work involves growing human muscles on chips to understand how skeletal muscle cells interact with neurons and tendons. This research aims to develop better models for studying muscle diseases, drug screening, and even applications in cellular agriculture and biorobotics.
-
Antimicrobial technologies & drug delivery platforms
Dr Aaron Elbourne is an ARC DECRA Fellow, Jack Brockhoff ECR Fellow, and Associate Professor within the School of Science at STEM Hub. A leader in nanomaterials, soft matter science, and interface research, Aaron’s work addresses critical challenges in health and the environment.
With a strong focus on translational research, Aaron’s work bridges the gap between fundamental science and practical applications. His leadership in creating innovative technologies, fostering academic-industry partnerships, and empowering future researchers underscores his commitment to advancing science and creating a meaningful impact.
